Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Roche Diagnostics has announced that it will support the Oxford Biomedical Research Centre - a partnership between the Oxford Radcliffe Hospitals NHS Trust and University of Oxford - in the development of solutions enabling improved genetic and cytogenetic testing.
Subscribe to our email newsletter
Using the next-generation sequencing technology of 454 Sequencing and high-density arrays of Roche NimbleGen, the Oxford Biomedical Research Centre (BRC) will work on improved solutions for the analysis of genetic diseases.
In the course of their research project, Oxford will install several 454 Genome Sequencer FLX systems, a next-generation sequencing platform characterized by long, highly accurate reads. In conjunction with 454 Sequencing, Oxford will employ NimbleGen arrays as a preparative tool for sequencing and genome-wide detection of copy number variation (CGH).
Alastair Buchan, director of the Oxford BRC, said: “Next generation sequencing and high density arrays are novel technologies with considerable clinical potential. Evaluation of these fits well with our strategy of driving innovation and translational research in medicine and we are very pleased to be working with Roche to evaluate these platforms.”